1 Impact of COVID-19 vaccine doses and viral waves on inflammatory and

2 immunological responses to COVID-19 infections in India

- 3 Kamal Kant Sharma¹, Uttara Partap², Yogesh Marathe¹, Sanaa Shaikh¹, Pradeep D'Costa³,
- 4 Gaurav Gupta⁴, Molin Wang^{5,6}, Wafaie W Fawzi^{2,5,7}, Kevin C Kain⁸, Nerges Mistry¹, Yatin
- 5 Dholakia¹

6 Affiliations:

- 7 ¹The Foundation for Medical Research, Mumbai, India
- 8 ²Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston,
- 9 Massachusetts, USA
- 10 ³King Edward Memorial Hospital and Research Centre, Pune, India
- 11 ⁴Saifee Hospital, Mumbai, India
- ⁵Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts,
- 13 USA
- ⁶Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA
- ¹⁵ ⁷Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA
- ⁸Department of Medicine, University of Toronto and University Health Network, Toronto, Ontario,
- 17 Canada
- 18

19 **Corresponding author:**

20

Dr. Yatin Dholakia

The Foundation for Medical Research

Dr. Kantilal J. Sheth Memorial Building

84-A, R.G. Thadani Marg

Worli, Mumbai 400 018, India

<u>yatindholakia@gmail.com,</u> Contact Number: +91 22 2493 4989

22 Abstract:

23	Background: Investigation of the effect of SARS-CoV-2 variants and COVID-19 vaccination on
24	inflammatory and immune response to SARS-CoV-2 infection is limited in South Asia.
25	Objectives: We aimed to examine the impact of COVID-19 vaccination and waves of COVID-
26	19 on inflammatory and immunological biomarkers among COVID-19 patients in India.
27	Methods: This cross-sectional analysis used baseline data from a randomized controlled trial
28	of vitamin D and zinc during COVID-19 infection in India (N=181). Blood samples and data
29	regarding vaccination doses were collected. The second (Delta) or third (Omicron) wave was
30	determined by date of enrolment. Mixed effects linear regression with robust standard
31	errors was used to examine associations between COVID-19 vaccination dose or wave at
32	enrolment and C-Reactive Protein (CRP), ferritin, lactate dehydrogenase (LDH), D-dimer,
33	interleukin-6 (IL-6), angiopoietin-2 (Ang-2), soluble triggering receptor expressed on myeloid
34	cells-1 (sTREM-1), immunoglobulin G (IgG) and immunoglobulin M (IgM).
35	Results: Compared to no vaccination, full vaccination was associated with lower LDH
36	(P<0.001), D-dimer (P=0.521) and Ang-2 (P=0.046), and higher IgG levels (P<0.001). Partial
37	vaccination was associated with lower IL-6 (P=0.040) and higher IgG (P<0.001). Enrolment
38	during the third wave was associated with lower IL-6 (P<0.001), CRP (P=0.056), IgM
39	(P=0.013), and IgG (P<0.001), but higher D-dimer levels (P<0.001).
40	Conclusions: COVID-19 vaccination status and SARS-CoV-2 variant influence the
41	inflammatory and immunologic response during SARS-CoV-2 infection, contributing to the
42	severity of clinical presentation.

43 Keywords: COVID-19, vaccine, variants, inflammation, immunology, biomarkers

- 44 Tables: 4, Figures: 0
- 45 Word count: 3762 (Introduction: 420, Discussion: 1346), Abstract: 223
- 46 **Competing interests:**
- 47 All authors declare no conflicts of interest.
- 48 **Registration**:
- 49 Clinical Trial Registry of India (CTRI): CTRI/2021/04/032593
- 50 (https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NTQ1MTA=&Enc=&userName=CTRI
- 51 /2021/04/032593)

52 **Ethical approval:**

- 53 This study was conducted in accordance with the Declaration of Helsinki, and informed
- 54 written consent was taken from study participants. Ethical approval was obtained from the
- 55 Institutional Review Board of the Harvard T.H. Chan School of Public Health (Protocol No.
- 56 IRB20-1425), the University Health Network Research Ethics Board (20-5775), the
- 57 Institutional Research Ethics Committee of the Foundation for Medical Research (IREC No.
- 58 FMR/IREC/C19/02/2020), the Institutional Review Board of Saifee Hospital (Project No.
- 59 EC/008/2020) and the KEM Hospital Research Centre Ethics Committee (KEMHRC ID No.
- 60 2027).

61 Author contributions:

- 62 KKS, UP, WWF, KCK, YD, and NM conceptualized the study along with YM, SS, PD, GG and
- 63 MW. KKS, YD, YM, SS, PD and GG were involved in data acquisition, and in study monitoring
- along with KCK, WWF, NM and UP. MW provided statistical expertise. KKS and UP analysed
- the data, KKS drafted the first draft of manuscript, and all authors reviewed and critically
- revised the draft and approved the final manuscript.
- 67

68 Introduction

COVID-19 infection is caused by the severe acute respiratory syndrome coronavirus 2 (SARSCoV-2), a major global health concern of the 21st century, and has affected more than 609
million people and caused over 6.5 million deaths worldwide.^[1] The ability of SARS-CoV-2
viruses to undergo frequent and random mutations may result in the development of highly
contagious and lethal variants, and this has extended the COVID-19 pandemic through
multiple waves of infection.^[1]

75 The progression of COVID-19 infection is associated with altered clinical manifestations and 76 changes in the level of related inflammatory and immunological biomarkers. Innate immune responses, coagulation, and the initiation of pro-inflammatory responses are common 77 pathways to counteract infectious agents, which may result in increased circulating levels of 78 acute phase proteins such as C-reactive protein (CRP), ferritin, and D-Dimer. In particularly 79 acute cases, the proliferation of the virus in the host cell and its rapid spread in other cells 80 results in a cytokine storm, which is considered a critical condition.^[2] The profile of human 81 82 immune response, transmission ability, laboratory characteristics, and antigenicity of the virus depends at least partially on the COVID-19 virus variant.^[3,4] While differences in 83 symptoms have been noted,^[5] there are limited data available on inflammatory and 84 immunological responses to different SARS-CoV-2 variants, particularly from South Asian 85 populations. 86

Protective immunity through vaccines was paramount to reducing the severity of COVID-19
disease and breaking the chain of transmission. India also scaled up its domestic vaccine
research and development program for the launch of the vaccination drive in the country by
January 2021 and has achieved over 2 billion vaccinations so far.^[6] Around 921 million

91	people had their first dose of the COVID-19 vaccine in India, 863 million were fully
92	vaccinated (2 doses), and around 139 million received their precautionary dose by
93	September 2022. ^[7] It has been observed that vaccination and its doses directly impact the
94	inflammatory and antibody response to SARS-CoV-2 infection. ^[8,9] However, evidence
95	regarding the effect of COVID-19 vaccination on the inflammatory and immunological
96	response among newly-infected patients remains limited, particularly from lower- and
97	middle-income populations such as those in South Asia. ^[10]
98	Few data have been reported on a comprehensive range of inflammatory and
99	
	immunological markers by COVID-19 vaccination doses and second versus third waves of
100	the COVID-19 pandemic (which roughly correspond to two distinct SARS-CoV-2 variants –
100 101	the COVID-19 pandemic (which roughly correspond to two distinct SARS-CoV-2 variants – Delta and Omicron respectively) from COVID-19 patients, particularly in India. In this study,
100 101 102	immunological markers by COVID-19 vaccination doses and second versus third waves of the COVID-19 pandemic (which roughly correspond to two distinct SARS-CoV-2 variants – Delta and Omicron respectively) from COVID-19 patients, particularly in India. In this study, we aimed to determine the association between COVID-19 vaccination doses and waves of
100 101 102 103	immunological markers by COVID-19 vaccination doses and second versus third waves of the COVID-19 pandemic (which roughly correspond to two distinct SARS-CoV-2 variants – Delta and Omicron respectively) from COVID-19 patients, particularly in India. In this study, we aimed to determine the association between COVID-19 vaccination doses and waves of COVID-19, and a set of inflammatory and immunological biomarkers, among SARS-CoV-2-

106 Materials and Methods

107 <u>Study procedures</u>

- 108 This analysis uses baseline data from a randomized controlled trial aiming to evaluate the
- 109 effects of vitamin D and zinc supplementation on COVID-19 outcomes in Maharashtra, India
- (ClinicalTrials.gov registration: NCT04641195).^[11] From April 2021 to February 2022,
- 111 hospitalized or home-isolated COVID-19 patients aged ≥18 years with a positive RT-PCR or
- rapid antigen test and with mild to moderate symptoms were enrolled from two study sites:
- 113 King Edward Memorial (KEM) Hospital and Research Centre, Pune, and Saifee Hospital,
- 114 Mumbai.

115	Details regarding study	procedures have b	een outlined previou	sly. ^[11] baseline procedures

- are briefly described as follows. At enrolment, background information, medical history, and
- 117 clinical symptoms were obtained and clinical assessment was conducted along with the
- 118 collection of blood samples for routine laboratory investigations and study of specific
- inflammatory and immunological biomarkers. In addition, participants were asked about
- 120 details of their COVID-19 vaccination status at baseline and during successive follow-ups.
- 121 Routine blood investigation included testing of CRP, lactate dehydrogenase (LDH), serum
- 122 ferritin, and D-dimer. This was performed at the respective hospital sites, which were
- accredited by the National Accreditation Board for Testing and Calibration
- 124 Laboratories (NABL). All COVID-19 treatment, such as medications, was delivered by
- 125 clinicians independently of the study, guided by the national treatment recommendations
- 126 for COVID-19 at the time.^[12]
- 127 Testing of other plasma biomarkers including angiopoietin-2 (Ang2), interleukin-6 (IL-6),
- soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), immunoglobulin G (IgG),

129	and immunoglobulin M (IgM) were conducted at the coordinating institute, The Foundation
130	for Medical Research (FMR). Blood samples collected were processed at hospital sites for
131	plasma, and the centrifuged matrix was transported to FMR adhering to the transportation
132	regulations provided by the Government of India (GOI) for COVID-19 samples. ^[13] Aliquots of
133	plasma were prepared for further testing and stored at -20°C. The concentration of
134	biomarkers was quantified using sandwich enzyme-linked immunosorbent assay (ELISA),
135	was performed according to the manufacturer's instructions; Thermofisher Invitrogen, USA
136	(IL-6, Ang-2, sTREM-1) and RayBiotech, USA (IgG and IgM) and readings were observed at
137	450 nm. Due to issues with the sample kit, sTREM-1 assays were performed only for a
138	subset of 48 participants. To ensure accurate results, the samples were run in triplicates.
139	Variables of interest
140	Exposures of interest were COVID-19 vaccination status and wave during which the
141	participant was enrolled. Participants were categorized based on their COVID-19 vaccination
142	doses received till the day of enrolment. Participants with no COVID-19 vaccine were
143	grouped as unvaccinated, those with one dose were partially vaccinated, and those who
144	received second dose and/or the final third (precautionary or booster) dose were
145	categorized as fully vaccinated. Participants were enrolled across two waves of the COVID-
146	19 pandemic in India. These waves were defined as wave 2 (predominantly Delta; enrolled
147	from the start of the study in April 2021 to 15^{th} December 2021), and wave 3
148	(predominantly Omicron; enrolled from 21 st December 2021, onwards – no participants
149	were enrolled between 15 th -21 st December 2021). ^[14]
150	Outcomes of interest were the following inflammatory and immunological biomarkers:
151	serum CRP, LDH, and ferritin, plasma D dimer, IL-6, Ang2, sTREM-1, IgG, and IgM. As part of

the analysis, we considered other potentially important participant characteristics including
sex, age, education, health behaviour (smoking and alcohol consumption), pre-existing
medical conditions, COVID-19 medication, body mass index (BMI), COVID-19 vaccine type,
median number of days with symptoms and median days since last vaccine dose before
enrolment.

157 Statistical analysis

158 First, baseline demographic, clinical, health behaviour, COVID-19 medication, and

anthropometric characteristics were compared across the two exposures of interest: 1)

160 COVID-19 vaccination and 2) COVID-19 waves. Differences between groups were examined

by Pearson's Chi-squared tests or Fisher's exact tests (comparisons with cell counts <5) for

162 categorical variables, and Wilcoxon rank sum tests or Kruskal Wallis tests (comparisons

across >2 groups) for continuous variables. We also examined median biomarker levels

across the two exposures of interest, testing for differences across groups using Wilcoxon

165 rank sum tests or Kruskal Wallis tests, as described above.

Following this, effects of the exposures of interest on each outcome were modelled using 166 mixed-effects linear regression with robust standard errors. Models were adjusted for the 167 other exposure (either COVID-19 vaccination or wave), and for age, sex, health behaviour 168 169 (smoking and alcohol consumption), pre-existing medical conditions, COVID-19 medication, BMI, COVID-19 vaccine type, and median number of days with symptoms and were 170 171 additionally adjusted for clustering at the hospital site level. Although we also initially included days since last vaccination in regression models, this variable was dropped due to 172 173 collinearity with the COVID-19 vaccination variable. Missing observations for covariates

were minimal (maximum: 2 participants [1.1%] for any covariate) and we assumed these
were missing completely at random. We used the missing indicator method to handle
missing data in regression models. All analyses were performed using STATA, version 14.1
(StataCorp, Texas).

178 Ethics

179 The procedures followed in this study were in accordance with the ethical standards of all

180 responsible ethical committees listed below, and with the Declaration of Helsinki, and

181 informed written consent was taken from study participants. Ethical approval was obtained

182 from the Institutional Review Board of the Harvard T.H. Chan School of Public Health

183 (Protocol No. IRB20-1425), the University Health Network Research Ethics Board (20-5775),

184 the Institutional Research Ethics Committee of the Foundation for Medical Research (IREC

185 No. FMR/IREC/C19/02/2020), the Institutional Review Board of Saifee Hospital (Project No.

186 EC/008/2020) and the KEM Hospital Research Centre Ethics Committee (KEMHRC ID No.

187 2027). The trial is registered on ClincialTrials.gov: NCT04641195, and Clinical Trial Registry of

188 India (CTRI): CTRI/2021/04/032593. Health Ministry Steering Committee (HSMC) - GOI

189 endorsement was received before the commencement of the study.

190 Results

191 Overall baseline and clinical characteristics of the enrolled participants

- 192 Total 181 COVID-19 patients were included in the study. The mean (SD) age of the study
- 193 participants was 47 (15.7) years, and the range was 18-87 years. One-fourth of participants
- 194 (24.8%) were 60 years of age or older. The proportion of male participants was 51.3%, and
- 195 91.8% of participants had received secondary or higher-level education. Around 62% of
- 196 participants were overweight or obese (30.9% in each category), only 6 individuals (3.3%)
- 197 were underweight and a normal BMI was found in 34.8% participants. The median
- 198 (interquartile range [IQR]) number of days with symptoms before enrolment was 3 days (2-
- 4). 39.7% of participants reported comorbidities such as hypertension (24.8%), diabetes
- 200 (20.9%), and cardiovascular disease (7.7%), and 19.8% of participants were on any COVID-19
- 201 medications. Among the antiviral medications, Remdesivir was used the most frequently
- 202 (12.2%) (Table 1).

Baseline characteristics of the enrolled participants across exposure variables (vaccination status and waves of COVID-19 pandemic in India)

At the time of enrolment, one-fifth (19.9%) of individuals were unvaccinated, 13.3% had

their first dose of COVID-19 vaccine, and 51.9% patients enrolled were fully vaccinated with

- 207 two or three doses; 14.9% did not provide information on their vaccination status. The
- 208 median days since last vaccine dose before enrolment was 126 days (IQR: 51-216). Fifty-
- 209 eight percent individuals received COVISHIELD vaccine by AstraZeneca and Serum Institute
- of India, 7.1% received COVAXIN (Bharat Biotech) which was approved and introduced later,
- 211 19.9% were unvaccinated at the time of enrolment, and rest around 15% did not provide
- their vaccination details (Table 1).

213	A greater proportion of unvaccinated and fully vaccinated individuals was male (P=0.049).
214	Additionally, a greater proportion of partially vaccinated individuals was in 30-44 years age
215	group (P=0.008), had graduate education (P=0.006), was enrolled during the second wave
216	(P<0.001), and was using any COVID-19 medications (P=0.061). Full vaccination was
217	common in older participants who were more than 44 years, and among those who
218	reported hypertension (P=0.023), any pre-existing conditions, and obesity. The median days
219	from last dose before enrolment in partially vaccinated participants was 61 days (IQR: 31-
220	92) while it was 167 ([range 77-241] days for the fully vaccinated group (<i>P</i> <0.001]) (Table 1).
221	Most (66.3%) of the study participants were enrolled during the second wave. A larger
222	proportion of participants who enrolled in the second wave were aged 30-44 years
223	(P=0.381), and had normal BMI compared to third wave participants (P=0.019). All
224	participants enrolled in the third wave had secondary or higher education whereas about
225	one tenth of those enrolled in the second wave had primary or less education (<i>P</i> =0.004).
226	Close to half (46%) of participants enrolled in the third wave were obese, compared with
227	23.3% of participants enrolled in the second wave (Table 1).
228	Levels of inflammatory and immunological biomarkers of COVID-19 infected participants
229	across vaccination status and waves of COVID-19 (unadjusted analyses)
230	We first compared unadjusted median biomarker levels across vaccination status at
231	enrolment and the COVID-19 wave in which the participants were enrolled. The unadjusted
232	median CRP, LDH, ferritin, D-dimer and IL-6 levels were lower in fully and partially
233	vaccinated groups as compared to the unvaccinated group (P<0.001 for LDH and IL-6, and P=
234	0.005 for ferritin). The unadjusted levels of other inflammatory markers Ang-2 and sTREM-1
235	were higher in both vaccinated groups than unvaccinated group, but not significant

236	(P=0.454 and P=0.977 respectively). Unadjusted IgG levels were significantly elevated in
237	vaccinated groups as compared to the unvaccinated group especially in partially vaccinated
238	people (P=0.009), while unadjusted IgM levels were also notably high in partially vaccinated
239	group and lower in fully vaccinated people (<i>P</i> =0.014) (Table 2).
240	The study participants enrolled in the second wave had a higher median level of unadjusted
241	CRP, LDH, ferritin, and IL-6 compared to individuals enrolled in the third wave (P<0.05 for
242	all). These participants also had lower unadjusted median D-dimer levels, though this was
243	not significant (<i>P</i> =0.155). Furthermore, unadjusted plasma levels of IgM and IgG antibodies
244	were significantly lower in the third wave compared with second wave participants (P<0.001
245	and P=0.019 respectively) (Table 2).
246	Regression analysis of effect of vaccination status and wave of COVID-19 pandemic on
247	inflammatory and immunological biomarkers (adjusted analyses)
247 248	inflammatory and immunological biomarkers (adjusted analyses) In fully-adjusted multivariable regression models, full vaccination (but not partial
247 248 249	inflammatory and immunological biomarkers (adjusted analyses) In fully-adjusted multivariable regression models, full vaccination (but not partial vaccination) was associated with lower LDH and Ang-2; LDH (β: -77.4, 95% CI: -89.3 – -65.4,
247 248 249 250	inflammatory and immunological biomarkers (adjusted analyses) In fully-adjusted multivariable regression models, full vaccination (but not partial vaccination) was associated with lower LDH and Ang-2; LDH (β: -77.4, 95% CI: -89.3 – -65.4, P<0.001) and Ang-2 (β: -61.0, 95%CI: -121.0 – -1.0, P=0.046) respectively. Full vaccination
247 248 249 250 251	inflammatory and immunological biomarkers (adjusted analyses) In fully-adjusted multivariable regression models, full vaccination (but not partial vaccination) was associated with lower LDH and Ang-2; LDH (β: -77.4, 95% CI: -89.3 – -65.4, P<0.001) and Ang-2 (β: -61.0, 95%CI: -121.0 – -1.0, P=0.046) respectively. Full vaccination was also associated with lower D-dimer levels, but the association did not reach statistical
247 248 249 250 251 252	inflammatory and immunological biomarkers (adjusted analyses) In fully-adjusted multivariable regression models, full vaccination (but not partial vaccination) was associated with lower LDH and Ang-2; LDH (β: -77.4, 95% CI: -89.3 – -65.4, P<0.001) and Ang-2 (β: -61.0, 95% CI: -121.0 – -1.0, P=0.046) respectively. Full vaccination was also associated with lower D-dimer levels, but the association did not reach statistical significance (β: -248.9, 95% CI:-1,009.4 – 511.7, P=0.521). Furthermore, partial and full
247 248 249 250 251 252 253	inflammatory and immunological biomarkers (adjusted analyses) In fully-adjusted multivariable regression models, full vaccination (but not partial vaccination) was associated with lower LDH and Ang-2; LDH (β: -77.4, 95% CI: -89.3 – -65.4, P<0.001) and Ang-2 (β: -61.0, 95%CI: -121.0 – -1.0, P=0.046) respectively. Full vaccination was also associated with lower D-dimer levels, but the association did not reach statistical significance (β: -248.9, 95% CI:-1,009.4 – 511.7, P=0.521). Furthermore, partial and full vaccination was associated with lower IL-6 levels as compared to no vaccination, with
247 248 249 250 251 252 253 254	inflammatory and immunological biomarkers (adjusted analyses) In fully-adjusted multivariable regression models, full vaccination (but not partial vaccination) was associated with lower LDH and Ang-2; LDH (β: -77.4, 95% CI: -89.3 – -65.4, P<0.001) and Ang-2 (β: -61.0, 95% CI: -121.0 – -1.0, P=0.046) respectively. Full vaccination was also associated with lower D-dimer levels, but the association did not reach statistical significance (β: -248.9, 95% CI:-1,009.4 – 511.7, P=0.521). Furthermore, partial and full vaccination was associated with lower IL-6 levels as compared to no vaccination, with similar magnitudes of difference for both groups but significant associations only for the
247 248 249 250 251 252 253 254 255	inflammatory and immunological biomarkers (adjusted analyses)In fully-adjusted multivariable regression models, full vaccination (but not partialvaccination) was associated with lower LDH and Ang-2; LDH (β: -77.4, 95% Cl: -89.3 – -65.4,P<0.001) and Ang-2 (β: -61.0, 95% Cl: -121.0 – -1.0, P=0.046) respectively. Full vaccination
247 248 249 250 251 252 253 254 255 256	inflammatory and immunological biomarkers (adjusted analyses)In fully-adjusted multivariable regression models, full vaccination (but not partialvaccination) was associated with lower LDH and Ang-2; LDH (β: -77.4, 95% CI: -89.3 – -65.4,P<0.001) and Ang-2 (β: -61.0, 95%CI: -121.0 – -1.0, P=0.046) respectively. Full vaccination

258 Although not significant, decreasing trends in CRP in partially vaccinated (β: -26.1, 95% CI: -

- 259 102.1 50.0, *P*=0.502) and fully vaccinated individuals (β : -28.5, 95% CI: -88.0 30.9,
- 260 P=0.347) were observed, similarly decreasing ferritin levels in partial and fully vaccinated
- 261 participants were also noticed (β: -38.7, 95% CI: -439.6– 362.2, *P*=0.850 and β: -177.4, 95%
- 262 CI: -691.3 336.5, *P*=0.499 respectively) (Table 3).
- 263 Significant associations between partial and full vaccination and elevated IgG were detected
- 264 (β: 61.5, 95% CI: 48.9 74.1, *P*<0.001, and β: 62.2, 95% CI: 56.7 67.6, *P*<0.001
- 265 respectively). Estimates suggested increased levels of IgM associated with partial
- vaccination. However, these estimates of increase were not significant, and were also not
- 267 statistically different from estimates for fully-vaccinated individuals, with fully overlapping
- 268 confidence intervals (Table 3).
- Additionally, in these fully-adjusted analyses, enrolment in the third wave was associated
- 270 with significantly lower IL-6 (β: -12.0, 95% CI: -12.6 -11.4, P<0.001), and CRP which was
- borderline significant (β : -21.7, 95% CI: -44.0 0.6, P= 0.056). On the other hand, higher D-
- 272 dimer values were significantly associated with enrolment in third-wave (β: 322.5, 95% CI:
- 80.9 564.2, *P*=0.009). Other inflammatory markers including ferritin, LDH, and Ang-2 levels
- 274 were also lower in third-wave versus second-wave participants, but differences in these
- biomarkers were not significant (Table 4).
- 276 Significant lower IgG and IgM were associated with enrolment in the third wave as
- 277 compared to second-wave; IgM (β : -23.6, 95% CI: -42.3 -4.9, *P*= 0.013) and IgG (β : -77.6,
- 278 95% CI: -99.4 -55.8, *P*<0.001) (Table 4).

280 Discussion

281	In this study, we found that levels of inflammatory markers, particularly LDH and Ang-2
282	were significantly lower in fully vaccinated participants compared to unvaccinated
283	participants with COVID-19. Furthermore, we observed some evidence of lower IL-6 levels in
284	both partially and fully vaccinated participants, and substantially elevated IgG levels in both
285	partially and fully vaccinated participants. We also found that infection during the third
286	wave was associated with lower CRP, IL-6, and IgG levels, and higher D-Dimer levels.
287	Inflammation is a defence mechanism that is activated by a coordinated signalling pathway,
288	and also regulates inflammatory mediator levels in host tissue cells and inflammatory cells
289	recruited from the blood. ^[15] Previous studies have shown that vaccinated patients have
290	reduced severity of COVID-19 disease compared to unvaccinated patients, and individuals
291	with different vaccination doses have variable immune-inflammatory characteristics
292	including the existence of higher neutralizing antibodies response and lower inflammatory
293	markers. ^[16,17]
294	CRP LDH, ferritin, D-dimer, and IL-6 are inflammatory markers explored commonly in COVID-
295	19 and other research studies. However, evidence on the association between COVID-19
296	vaccination and variants and other inflammatory markers such as Ang-2 and sTREM-1, as
297	performed in our study, is scarce – we were unable to find any relevant studies during our
298	search of the literature on these associations. Some previous studies, including from South
299	Asia, have examined the relation between COVID-19 vaccination or variants and commonly
300	measured inflammatory and immunological markers. ^[10,18,19] Similar to our study, data from
301	these previous reports suggest generally inverse associations between vaccination against
302	COVID-19 and commonly measured inflammatory markers, and positive associations

between vaccination and immunological markers^[10,18,19]. For example, an observational 303 304 study conducted in Pakistan on a cohort of 434 COVID-19 patients reported significantly higher LDH, ferritin, and D-dimer levels in unvaccinated individuals compared to vaccinated 305 individuals.^[18] In another study comparing unvaccinated COVID-19 patients with the fully 306 307 vaccinated group, significantly lower levels of IL-6 along with CRP and D-dimer were reported in the fully vaccinated group. This study also showed noticeably higher IgG in fully 308 vaccinated individuals.^[19] Similarly, significantly higher IgG levels among partially vaccinated 309 310 individuals were also observed in our study.

Also corroborating our results, a recent observational study conducted in India on 1160 311 312 hospitalized COVID-19 patients found similar trends of immunological and inflammatory biomarkers. This included raised D-Dimer levels reported after the first vaccination, but 313 lower levels after 2 or 3 doses, and non-significant declining CRP.^[10] Taken together with 314 these previous data, the lower CRP, LDH, ferritin, D-dimer, Ang-2, and IL-6 inflammatory 315 316 mediators among vaccinated individuals in our study add to the evidence that vaccineinduced protection with higher immunological mediators may help to reduce inflammation, 317 which has been associated with more severe clinical outcomes in COVID-19.^[20] 318

Previous evidence also suggests that the SARS-CoV-2 Omicron variant is less severe compared to other variants, and limited data from previous reports suggest that the Omicron variant may induce a smaller inflammatory and immune response.^[8,21,22] The possible reasons noted are less effective replication in the lung parenchyma,^[23] and sustained conservation of T-cell mediated immunity from previous infection or vaccination.^[24] A study conducted in Australia assessed severity of COVID-19 variants through laboratory findings, and observed lower inflammatory markers, particularly ferritin,

LDH, and CRP levels, linked with Omicron variant compared to Delta variant. This study also 326 found no significant differences in D-dimer levels.^[8] A recent comparative study of the three 327 waves of COVID-19 in India reported that infection with the Omicron variant versus Delta 328 variant was associated with significantly lower levels of CRP and IL-6.^[21] Another study 329 330 conducted in Bangladesh reported higher levels of IgG, and higher risk of hospitalization and oxygen support were associated with infection with the Delta compared to Omicron 331 variant.^[22] Contributing to growing evidence suggesting that the Omicron variant is 332 333 associated with less severe disease, our study also suggests that participants enrolled in waves of infection corresponding to the Omicron variant had lower inflammatory and 334 immunological biomarkers. 335 Contrary to other inflammatory biomarkers, D-dimer concentration in our study was 336 substantially higher in the third wave compared to the second wave participants. A study on 337 D-dimer levels suggested that early management of infection with steroids and 338 339 anticoagulants in the second wave may affect the production of D-dimer and limit the 340 endothelial damage, however, only a few participants were on steroids and anticoagulants in our study.^[25] Other reasons could be greater proportion of elderly individuals and high 341 BMI reported in the third wave in our study which are independent risk factors of high D-342 dimer levels.^[26,27] Importantly, we adjusted for these factors in analyses, suggesting that 343 other unmeasured clinical factors may underlie the observed associations. 344 345 The immune response is a dynamic process that might also change the inflammatory 346 parameters. Inflammatory response increases rapidly during the initial phase of infection and falls during the recovery period, therefore, longitudinal changes in inflammatory 347 markers are more important rather than values of biomarkers at a single time point.^[28] 348

Typically, after the onset of symptoms, immunological markers IgM and IgG can be detected 349 during the first week and at around two weeks respectively,^[29] and gradually these 350 antibodies decline with time. The current study suggests that antibodies were higher among 351 vaccinated participants who later became ill with COVID-19 compared with unvaccinated 352 individuals. Particularly IgG antibodies remained high even after receiving two or three 353 vaccine doses compared to those who did not receive any vaccine doses. Together with 354 recent evidence from India indicating the effect of IgG levels on COVID-19-related measures 355 such as viral emission^[30] these findings help characterize the biological effects of COVID-19 356 vaccination that may underlie disease severity and outcomes among SARS-CoV-2-infected 357 individuals. 358

This study has a few limitations. Information on prior COVID-19 infection was not collected 359 from the study participants which could affect in the vaccine-induced immune response and 360 its impact on inflammatory biomarkers. Secondly, different types of COVID-19 vaccines can 361 362 elicit diverse antibody responses, although in this study most (89%) of participants had received the adenoviral vector vaccine (COVISHIELD) in comparison to the whole cell 363 inactivated virus (COVAXIN). Additionally, genome sequencing for confirmation of COVID-19 364 variants was not performed in this study, and classification of two waves of the COVID-19 365 pandemic was made based on defined time points by the federal COVID-19 task forces and 366 previous research articles.^[14] Therefore, there is the possibility that participants enrolled at 367 368 beginning of the third wave may have been infected with either the Delta or the Omicron 369 variant of the SARS-CoV-2 virus. Analyses were based on a small sample size, particularly for unvaccinated individuals in the third wave – which was likely due to good uptake of vaccines 370 during the study period. This may have limited our ability to detect associations in certain 371 cases, as evidenced by the wide confidence intervals for linear regression estimates. 372

Additionally, this study was based among individuals with mild-to-moderate COVID-19 373 symptoms and no severe outcomes, meaning that we were unable to clearly examine the 374 effect of vaccination status, wave of enrolment, and biomarker levels on clinical outcomes. 375 376 The foremost strength of this study is the diverse set of inflammatory and immunological biomarkers of COVID-19 infection explored, which gives an opportunity to understand the 377 378 biological changes related to infection that are affected by prior COVID-19 vaccination and by SARS-CoV-2 variants. Furthermore, we were able to account for a range of potential 379 380 demographic, clinical and health-related confounders by adjusting for these in final regression models. Changes in trends cross unadjusted and adjusted analyses suggested the 381 importance of accounting for these characteristics when drawing conclusions regarding the 382 potential effect of vaccination status and COVID-19 wave on biomarker levels. Additionally, 383 384 this study also provides indicative data on the different clinical manifestations of two SARS-CoV-2 variants of concern. The study setting in India enables applicability of findings to the 385 386 wider South Asia context where evidence on the effect of COVID-19 vaccine and SARS-CoV-2 variants on inflammatory and immunological responses to SARS-CoV-2 infection remains 387 388 scarce.

389 Conclusion

This study indicates that the inflammatory and immunologic response to SARS-CoV-2 infection may be least partly associated with prior COVID-19 vaccination status and with the SARS-CoV-2 variant. This study provides data outlining potential pathways through which COVID-19 vaccination may protect against, and SARS-CoV-2 variants may influence, the likelihood of severe disease.

3	9	5

396 References

- WHO. COVID-19 Weekly Epidemiological Update: Edition 122 Published 14 December
 2022. Geneva: World Health Organization; 2022.
- Hong LZ, Shou ZX, Zheng DM, Jin X. The most important biomarker associated with
 coagulation and inflammation among COVID-19 patients. Mol Cell Biochem
 2021;476(7):2877–85.
- Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol
 2021;19(7):409–24.
- 405 4. Davies MA, Kassanjee R, Rousseau P, Morden E, Johnson L, Solomon W, et al.
 406 Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth
 407 wave compared with previous waves in the Western Cape Province, South Africa. Trop
 408 Med Int Health 2022;27(6):564–73.
- Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, et al. Symptom
 prevalence, duration, and risk of hospital admission in individuals infected with SARSCoV-2 during periods of omicron and delta variant dominance: a prospective
 observational study from the ZOE COVID Study. The Lancet 2022;399(10335):1618–24.
- 413 6. Ministry of Health and Family Welfare. CoWIN [Internet]. 2022 [cited 2023 Mar
 414 9];Available from: https://www.cowin.gov.in/
- 415 7. Ministry of Health and Family Welfare. Cumulative Coverage Report of COVID-19
 416 Vaccination 28 September 2022. New Delhi: Ministry of Health and Family Welfare,
 417 Government of India; 2022.
- Wang J, Choy KW, Lim HY, Ho P. Laboratory markers of severity across three COVID-19
 outbreaks in Australia: has Omicron and vaccinations changed disease presentation?
 Intern Emerg Med 2023;18(1):43–52.
- Brown PE, Fu SH, Bansal A, Newcombe L, Colwill K, Mailhot G, et al. Omicron BA.1/1.1
 SARS-CoV-2 Infection among Vaccinated Canadian Adults. N Engl J Med
 2022;386(24):2337–9.
- Munigela A, Sowpati DT, M S, Banu S, Siva AB, V JK, et al. Clinical outcomes in
 individuals hospitalized with SARS-CoV-2 Delta variant (B.1.617.2) who had been
 vaccinated with Covishield (ChAdOx1) and Covaxin (BBV-152). IJID Reg 2022;5:104–10.
- Sharma KK, Partap U, Mistry N, Marathe Y, Wang M, Shaikh S, et al. Randomised trial to
 determine the effect of vitamin D and zinc supplementation for improving treatment
 outcomes among patients with COVID-19 in India: trial protocol. BMJ Open
 2022;12(8):e061301.

- 431 12. MOHFW, GOI. Clinical Management Protocol for COVID-19 (In Adults) Version 6
 432 (24.05.21) [Internet]. New Delhi: Ministry of Health and Family Welfare, Government
 433 of India; 2021 [cited 2022 Feb 28]. Available from:
 434 https://www.mohfw.gov.in/pdf/UpdatedDetailedClinicalManagementProtocolforCOVI
- 435 D19adultsdated24052021.pdf
- Indian Council for Medical Research, National Institute of Virology. Specimen
 Collection, Packaging and Transport Guidelines for 2019 novel Coronavirus (2019nCoV) [Internet]. New Delhi: Ministry of Health and Family Welfare, Government of
 India; 2020 [cited 2023 Mar 9]. Available from:
- 440 https://www.mohfw.gov.in/pdf/5Sample%20collection_packaging%20%202019441 nCoV.pdf
- 442 14. Mahajan NN, Kesarwani S, Salunke C, Kumbhar P, Yenkure P, Shaikh J, et al. Clinical
 443 presentation, pregnancy complications, and outcomes of pregnant women with
 444 COVID-19 during the Omicron-dominant third wave in Mumbai, India. Int J Gynecol
 445 Obstet 2022;159(3):968–73.
- Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb
 Perspect Biol 2009;1(6):a001651.
- Bahl A, Johnson S, Maine G, Garcia MH, Nimmagadda S, Qu L, et al. Vaccination
 reduces need for emergency care in breakthrough COVID-19 infections: A multicenter
 cohort study. Lancet Reg Health Am 2021;4:100065.
- 451 17. Gupta N, Kaur H, Yadav PD, Mukhopadhyay L, Sahay RR, Kumar A, et al. Clinical
 452 Characterization and Genomic Analysis of Samples from COVID-19 Breakthrough
 453 Infections during the Second Wave among the Various States of India. Viruses
 454 2021;13(9):1782.
- Fatima S, Zafar A, Afzal H, Ejaz T, Shamim S, Saleemi S, et al. COVID-19 infection among
 vaccinated and unvaccinated: Does it make any difference? PloS One
 2022;17(7):e0270485.
- 458 19. Wang C, Li Y, Pan Y, Zhou L, Zhang X, Wei Y, et al. Clinical and immune response
 459 characteristics among vaccinated persons infected with SARS-CoV-2 delta variant: a
 460 retrospective study. J Zhejiang Univ Sci B 2022;23(11):899–914.
- 20. Thwaites RS, Sanchez Sevilla Uruchurtu A, Siggins MK, Liew F, Russell CD, Moore SC, et
 al. Inflammatory profiles across the spectrum of disease reveal a distinct role for GMCSF in severe COVID-19. Sci Immunol 2021;6(57):eabg9873.
- Singh S, Sharma A, Gupta A, Joshi M, Aggarwal A, Soni N, et al. Demographic
 comparison of the first, second and third waves of COVID-19 in a tertiary care hospital
 at Jaipur, India. Lung India Off Organ Indian Chest Soc 2022;39(6):525–31.
- 467 22. Ghosh AK, Landt O, Yeasmin M, Sharif M, Ratul RH, Molla MA, et al. Clinical
 468 Presentation of COVID-19 and Antibody Responses in Bangladeshi Patients Infected
 469 with the Delta or Omicron Variants of SARS-CoV-2. Vaccines 2022;10(11):1959.

- 470 23. Hui KPY, Ho JCW, Cheung MC, Ng KC, Ching RHH, Lai KL, et al. SARS-CoV-2 Omicron
 471 variant replication in human bronchus and lung ex vivo. Nature 2022;603(7902):715–
 472 20.
- 473 24. Choi SJ, Kim DU, Noh JY, Kim S, Park SH, Jeong HW, et al. T cell epitopes in SARS-CoV-2
 474 proteins are substantially conserved in the Omicron variant. Cell Mol Immunol
 475 2022;19(3):447–8.
- Porfidia A, Porceddu E, Talerico R, Montalto M, Landi F, Pola R. Second wave of the
 COVID-19 pandemic: D-dimer levels are not so high anymore. J Thromb Thrombolysis
 2021;52(3):779–81.
- 479 26. Harper PL, Theakston E, Ahmed J, Ockelford P. D-dimer concentration increases with
 480 age reducing the clinical value of the D-dimer assay in the elderly. Intern Med J
 481 2007;37(9):607–13.
- 482 27. Tita-Nwa F, Bos A, Adjei A, Ershler WB, Longo DL, Ferrucci L. Correlates of D-dimer in
 483 older persons. Aging Clin Exp Res 2010;22(1):20–3.
- 484 28. Kim MJ, Lee EB, Song YW, Park JK. Profile of common inflammatory markers in
 485 treatment-naïve patients with systemic rheumatic diseases. Clin Rheumatol
 486 2020;39(10):2899–906.
- 487 29. Lau CS, Phua SK, Liang YL, Oh HML, Aw TC. Robust SARS-CoV-2 Antibody Responses in
 488 Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19
 489 Vaccine. Vaccines 2021;9(11):1241.
- 30. Sriraman K, Shaikh A, Vaswani S, Mestry T, Patel G, Sakthivel S, et al. Impact of COVID19 vaccination on transmission risk of breakthrough infections: Lessons from adapted
 N95 mask sampling for emerging variants and interventions. J Med Virol
 2023;95(1):e28188.
- 494

496 **Tables**

Table 1. Baseline characteristics of enrolled participants (N=181).

N (%)									
	Overall (181)	COVID-19 Vaccin	COVID-19 Vaccination status					COVID -19 Waves	
		Unvaccinated n=36	Partially vaccinated n=24	Fully vaccinated n=94	Missing n=27		Second wave n=120	Third wave n=61	
Sex n (%)									
Female	88 (48.6)	17(47.2)	12(50.0)	46(48.9)	13(48.1)		54(45.0)	34(55.7)	
Male	93 (51.3)	19(52.8)	12(50.0)	48(51.1)	14(51.9)	— 0.049	66(55.0)	27(44.3)	- 0.172
Age, years, n (%)									
18-29	30 (16.5)	5(13.9)	3(12.5)	13(13.8)	9(33.3)		19(15.8)	11(18.0)	
30-44	55 (30.3)	18(50.0)	12(50.0)	19(20.2)	6(22.2)	0008	41(34.2)	14(23.0)	0.381
45-59	51 (28.1)	9(25.0)	5(20.8)	31(33.0)	6(22.2)	0.008	30(25.0)	21(34.4)	
≥60	45 (24.8)	4(11.1)	4(16.7)	31(33.0)	6(22.2)		30(25.0)	15(24.6)	
Education, n (%)									
Illiterate, no formal, Primary	15 (8.2)	8(22.2)	1(4.2)	3(3.2)	3(11.1)		15(12.5)	0(0.0)	
Secondary or senior secondary	54 (29.8)	8(22.2)	5(20.8)	34(36.2)	7(25.9)	0.006	36(30.0)	18(29.5)	
Graduate	65 (35.9)	8(22.2)	12(50.0)	36(38.3)	9(33.3)	0.006	36(30.0)	29(47.5)	0.004
Post-graduate	45 (24.8)	12(33.3)	6(25.0)	19(20.2)	8(29.6)		32(26.7)	13(21.3)	
Missing	2 (1.1)	0(0.0)	0(0.0)	2(2.1)	0(0.0)		1(0.8)	1(1.6)	
Health Behaviour, n (%)									
Smoking	8 (4.4)	2(5.6)	0(0.0)	5(5.3)	1(3.7)	0.736	7(5.8)	1(1.6)	0.270
Current alcohol use (n=180)	19 (10.6)	2(5.6)	3(12.5)	13(14.0)	1(3.7)	0.427	10(8.33)	9(14.75)	0.189
Missing alcohol (n=1)	1(0)	0(0.0)	0(0.0)	1(1.06)	0(0.0)		1(0.83)	0(0)	
Pre-existing conditions, n (%)									
Hypertension	45 (24.8)	4(11.1)	4(16.7)	31(33.0)	6(22.2)	0.023	28(23.3)	17(27.9)	0.505

Table 1. Baseline characteristics of enrolled participants (N=181).

N (%)									
	Overall (181)	COVID-19 Vaccina	COVID-19 Vaccination status					COVID -19 Waves	
		Unvaccinated n=36	Partially vaccinated n=24	Fully vaccinated n=94	Missing n=27		Second wave n=120	Third wave n=61	
Diabetes	38 (20.9)	9(25.0)	3(12.5)	22(23.4)	4(14.8)	0.472	26(21.7)	12(19.7)	0.755
Heart disease	14 (7.7)	3(8.3)	1(4.2)	7(7.5)	3(11.1)	0.911	11(9.2)	3(4.9)	0.389
Asthma	7 (3.8)	2(5.6)	0(0.0)	4(4.3)	1(3.7)	0.605	4(3.3)	3(4.9)	0.689
Neurological conditions	4 (2.2)	1(2.8)	0(0.0)	0(0.0)	3(11.1)	0.390	3(2.5)	1(1.6)	1.000
Chronic kidney disease	3 (1.6)	2(5.6)	0(0.0)	1(1.1)	0(0.0)	0.200	2(1.7)	1(1.6)	1.000
Chronic obstructive pulmonary disease	1 (0.5)	1(2.8)	0(0.0)	0(0.0)	0(0.0)	0.390	1(0.8)	0(0.0)	1.000
Other (Thyroid ,TB , cancer etc)	8 (4.4)	3(8.3)	1(4.2)	2(2.1)	2(7.4)	0.131	6(5.0)	2(3.3)	0.719
Any pre-existing condition	72 (39.7)	13(36.1)	7(29.2)	43(45.7)	9(33.3)	0.270	49(40.8)	23(37.7)	0.684
COVID-19 medication, n (%)									
Favipiravir	3 (1.6)	1(2.8)	0(0.0)	2(2.1)	0(0.0)	1.000	3(2.5)	0(0.0)	0.552
Remdesivir	22(12.2)	1(2.8)	4(16.7)	15(16.0)	2(7.4)	0.101	16(13.3)	6(9.8)	0.496
Dexamethasone	1 (0.5)	0(0.0)	0(0.0)	1(1.1)	0(0.0)	1.000	1(0.8)	0(0.0)	1.000
Monoclonal antibodies	8 (4.4)	1(2.8)	2(8.3)	5(5.3)	0(0.0)	0.765	8(6.7)	0(0.0)	0.053
Molnupiravir	5 (2.8)	0(0.0)	1(4.2)	4(4.3)	0(0.0)	0.541	0(0.0)	5(8.2)	0.004
Clexan	1 (0.5)	0(0.0)	0(0.0)	1(1.1)	0(0.0)	1.000	0(0.0)	1(1.6)	0.337
Any COVID-19 Medication	36 (19.8)	3(8.3)	7(29.2)	24(25.5)	2(7.4)	0.061	25(20.8)	11(18.0)	0.655
BMI (kg/m²), n (%)									
<18.5	6 (3.3)	1(2.8)	2(8.3)	2(2.1)	1(3.7)		4(3.3)	2(3.3)	
18.5-24.9	63 (34.8)	13(36.1)	9(37.5)	29(30.9)	12(44.4)	0.473	46(38.3)	17(27.9)	0.019
25-29.9	56 (30.9)	13(36.1)	6(25.0)	26(27.7)	11(40.7)	_	42(35.0)	14(23.0)	_

Table 1. Baseline characteristics of enrolled participants (N=181)	.81).
--	-------

N (%)									
	Overall (181)	COVID-19 Vaccina	Р	COVID -19 W	aves	Ρ			
		Unvaccinated n=36	Partially vaccinated n=24	Fully vaccinated n=94	Missing n=27		Second wave n=120	Third wave n=61	
≥30	56 (30.9)	9(25.0)	7(29.2)	37(39.4)	3(11.1)	_	28(23.3)	28(45.9)	-
Median number of days with symptoms (IQR)	3 (2-4)	3(2-5)	3(2-5)	2(2-3)	4(2-6)	0.154	3 (2-5)	2 (2-3)	0.105
COVID-19 waves during enrolment, r	n (%)								
Second wave ¹	120 (66.3)	35(97.2)	19(79.2)	40(42.6)	26(96.3)	- <0.001			
Third wave ¹	61 (33.7)	1(2.8)	5(20.8)	54(57.5)	1(3.7)	- <0.001	-		
COVID-19 vaccination status, n (%)									
Unvaccinated	36(19.9)	_					35(29.2)	1(1.6)	_
First Dose	24(13.3)						19(15.8)	5(8.2)	<0.001
Second /Booster dose	94(51.9)						40(33.3)	54(88.5)	<0.001
Missing	27(14.9)	-					26(21.7)	1(1.6)	-
Median days of last vaccine dose before enrolment (IQR) (n=118)	126 (51- 216)	-	61 (31-92)	167 (77-241)	-	<0.001	85 (45-169)	201 (111- 274)	<0.001
COVID-19 vaccine type n (%)									
Covishield (AstraZeneca and SII)	105 (58.1)	-	22(91.7)	83(88.3)	-	_	50(41.7)	55(90.2)	_
Covaxin (Bharat Biotech)	13 (7.1)	-	2(8.3)	11(11.7)	-	0.482	9 (7.5)	4(6.6)	0.119
Unvaccinated at enrolment	36 (19.9)	36 (100)	-	-	-	_	35 (29.1)	1(1.6)	-
Missing	27(14.9)	-	-	-	27(100.0)		26(21.7)	1(1.6)	

Unvaccinated: received no doses of COVID-19 vaccine. Partially vaccinated: received 1 dose of COVID-19 vaccine. Fully vaccinated: received 2 or 3 doses of COVID-19 vaccine.

Differences between categories were tested using Pearson's Chi-squared tests (Fisher's exact tests for cell count < 5) for categorical variables and Wilcoxon rank sum tests used for continuous variables. The second wave of the COVID-19 pandemic in India was defined as the period spanning approximately April 2021 (when study enrolment began) to December 15th, 2021. The third wave was defined as the period spanning from December 21st, 2021, onwards.

Table 2. Median (interquartile range) levels of inflammatory and immunological biomarkers overall and across participant characteristics.									
	Inflammatory markers							Immunological markers	
	CRP (mg/L) (N=176)	LDH (IU/L) (N=154)	Serum Ferritin (ng/ml) (N=160)	D-dimer (ng/ml) (N=168)	IL-6 (pg/ml) (N=178)	Ang-2 (pg/ml) (N=178)	sTREM-1 (pg/ml) (N=48)	lgM (U/mL) (N=177)	lgG (U/mL) (N=177)
Overall median, IQR Vaccination status	13.4 (5.0-34.6)	244 (199-321)	153 (61-311)	426 (291-670)	5.1 (2.7-10.5)	1,198 (848-1,690)	148 (66-148)	3.1 (1.1-7.0)	7.1 (0.6-86.8)
Unvaccinated	24.1 (5.4-50.6)	290 (220-342)	215 (124-490)	450 (319-718)	9.0 (4.0-13.7)	1,012 (770-1,703)	144 (27-188)	3.3 (1.3-5.9)	1.2 (0.4-98.3)
Partially Vaccinated	14.1 (5.6-39.6)	297 (217-338)	112 (65-515)	475 (288-768)	5.1 (2.5-9.0)	1,226 (933-1,544)	145 (68-169)	5.4 (1.7-14.2)	31.2 (5.3-165.5)
Fully Vaccinated	12.2 (4.6-34.9)	225 (186-274)	124 (43-215)	372 (274-573)	4.3 (2.3-7.4)	1,238 (913-1,646)	150 (23-283)	1.9 (0.8-4.9)	7.5 (1.0-63.5)
Р	0.504	<0.001	0.005	0.202	<0.001	0.454	0.977	0.014	0.009
COVID-19 wave									
Second wave ²	16.2 (5.4-50.6)	271 (205-337)	194 (102-461)	468 (288-744)	6.1 (2.2-10.7)	1,130 (767-1,736)	148 (66-184)	5.3 (2.2-10.7)	13.8 (1.0-110.9)
Third wave ³	9.9 (4.5-26.0)	225 (191-276)	101 (32-169)	381 (296-515)	4.1 (0.5-2.3)	1,286 (1,000-1,590)	-	1.4 (0.5-2.3)	3.2 (0.5-16.5)
Р	0.028	0.014	<0.001	0.155	0.008	0.322	-	<0.001	0.019

Unvaccinated: received no doses of COVID-19 vaccine. Partially vaccinated: received 1 dose of COVID-19 vaccine. Fully vaccinated: received 2 or 3 doses of COVID-19 vaccine. IQR: interquartile range.

Unadjusted medians (IQR) are reported for all biomarkers (please refer to Tables 3 and 4 for adjusted analyses).

P values are based on Wilcoxon's rank sum test (2 groups), or Kruskal Wallis test (multiple groups).

The second wave of the COVID-19 pandemic in India was defined as the period spanning approximately April 2021 (when study enrolment began) to December 15th, 2021. The third wave was defined as the period spanning from December 21st, 2021, onwards.

Table	3.	Estimates	of	association	between	COVID-19	vaccination	status	and	inflammatory	and
immunological biomarkers.											

	β Coefficient (95% Conf. Interval)	Р
CRP (mg/L)		
Partially vaccinated	-26.1 (-102.1-50.0)	0.502
Fully Vaccinated	-28.5 (-88.0-30.9)	0.347
LDH (IU/L)		
Partially vaccinated	9.3 (-31.7-50.2)	0.658
Fully Vaccinated	-77.4 (-89.365.4)	<0.001
Serum Ferritin (ng/ml)		
Partially vaccinated	-38.7 (-439.6-362.2)	0.850
Fully Vaccinated	-177.4 (-691.3-336.5)	0.499
D-Dimer (ng/ml)		
Partially vaccinated	95.4 (-450.3-641.2)	0.732
Fully Vaccinated	-248.9 (-1,009.4-511.7)	0.521
IL-6 (pg/ml)		
Partially vaccinated	-41.8 (-81.71.9)	0.040
Fully Vaccinated	-36.3 (-81.4-8.9)	0.116
Angiopoietin-2 (pg/ml)		
Partially vaccinated	1.5 (-379.9-382.9)	0.994
Fully Vaccinated	-61.0 (-121.01.0)	0.046
sTREM-1 (pg/ml)		
Partially vaccinated	16.5 (-91.4-124.3)	0.765
Fully Vaccinated	72.6 (70.6-74.5)	<0.001
IgM (U/mL)		
Partially vaccinated	52.7 (-145.7-251.0)	0.603
Fully Vaccinated	-13.9 (-43.6-15.9)	0.360
lgG (U/mL)		
Partially vaccinated	61.5 (48.9-74.1)	<0.001
Fully Vaccinated	62.2 (56.7-67.6)	<0.001
	COV/ID 10 upgeting. Destingly upgeting to during a f COV/ID 10.	

Unvaccinated: received no doses of COVID-19 vaccine. Partially vaccinated: received 1 dose of COVID-19 vaccine. Fully vaccinated: received 2 or 3 doses of COVID-19 vaccine.

95% CI: 95% confidence interval.

Estimates based on mixed effect regression models with robust standard errors.

The comparison group in the model is unvaccinated participants.

The model is adjusted for wave enrolled, age, gender, type of vaccine, BMI, COVID medications, pre-existing diseases, days of symptoms, health behaviour (drinking and smoking), and clustered by hospital sites.

501

Table 4. Estimates of association between COVID -19 waves and inflammatory and immunological biomarkers.					
	β Coefficient (95% Conf. Interval)	Р			
CRP (mg/L)	· · · · · ·				
Enrolled wave 3	-21.7 (-44.0-0.6)	0.056			
LDH (IU/L)					
Enrolled wave 3	-14.4 (-30.8-1.9)	0.084			
Serum ferritin (ng/ml)					
Enrolled wave 3	-29.1 (-171.1-112.9)	0.688			
D-Dimer (ng/ml)					
Enrolled wave 3	322.5 (80.9-564.2)	0.009			
IL-6 (pg/ml)					
Enrolled wave 3	-12.0 (-12.611.4)	<0.001			
Angiopoietin-2 (pg/ml)					
Enrolled wave 3	-26.5 (-139.1-86.0)	0.644			
sTREM-1 (pg/ml)					
Enrolled wave 3					
IgM (U/mL)					
Enrolled wave 3	-23.6 (-42.34.9)	0.013			
IgG (U/mL)					
Enrolled wave 3	-77.6 (-99.455.8)	<0.001			

95% CI: 95% confidence interval.

Estimates based on mixed effects regression models with robust standard errors

The comparison group is wave 2 participants

The model is adjusted for age, gender, vaccination status (unvaccinated: 0 doses of COVID-19 vaccine, partially vaccinated: 1 dose, fully vaccinated: 2 or 3 doses) and type of vaccine, BMI, COVID medications, pre-existing diseases, days of symptoms, health behaviour (drinking and smoking), and clustered by hospital sites.

The second wave of the COVID-19 pandemic in India was defined as the period spanning approximately April 2021 (when study enrolment began) to December 15th, 2021. The third wave was defined as the period spanning from December 21st, 2021, onwards.

502